About Us — Enbiosis SA

Scientific Foundations

Fifteen years ahead of the data

In 2004, while pursuing his PhD at the University of Nebraska-Lincoln, Prof. Dr. Özkan Ufuk Nalbantoğlu envisioned something far ahead of its time: analysing the human microbiome using artificial intelligence. At that moment, the technology to even generate such data did not yet exist.

Years later, as next-generation sequencing matured, the algorithms Prof. Nalbantoğlu had developed were adopted by the Earth Microbiome Project — the world’s largest microbiome initiative. What began as a theoretical study had evolved into a globally recognised scientific infrastructure.

From 2014 onward, Prof. Nalbantoğlu pushed the work further, developing algorithms not only to analyse the microbiome, but to modulate it in ways that could directly improve human health. That body of work, refined across more than fifteen years in bioinformatics and microbiome research, became the scientific foundation on which Enbiosis SA was built.

Assoc. Prof. Özkan Ufuk Nalbantoğlu
Chief Technical Officer (CTO)

Visionary Leadership

Ömer Özkan is a serial entrepreneur and early-stage investor with an unusual appetite for high-conviction bets in deep-tech and science-led sectors. Over the past decade, he has invested across solar energy, legal technology, education, autonomous systems and healthcare — backing companies that challenge incumbents through technology rather than incrementalism.

The pivotal moment came in 2018, when Özkan met Prof. Nalbantoğlu. Struck by the depth of his academic background and the clarity of his long-range vision, Özkan became convinced that the microbiome could redefine how we diagnose and treat disease. Enbiosis SA was founded in 2019, and from that moment on, Özkan closed every other chapter of his career to dedicate himself to one mission: turning microbiome science into a global health company.

Ömer Özkan
Chief Executive Officer (CEO)

The Technology

Technology Journey

Enbiosis SA has evolved in two distinct generations. The first established us as a clinically-validated leader in microbiome-based personalised nutrition. The second is a category-defining leap into Digital Twin & AI-powered nutraceuticals.

Generation One

Enbioma — Microbiome Analysis & Personalised Nutrition

Enbioma is an AI-powered SaaS platform that analyses gut microbiome data and generates personalised nutrition strategies for microbiome modulation. It holistically evaluates the relationship between the trillions of bacteria in the gut and the individual’s general health parameters, then designs an optimal diet strategy to drive each microbiome profile toward a healthier state.

The platform runs on a large and growing base of global microbiome data — tens of thousands of profiles today, growing every day. It is delivered as a cloud-based system that allows partners (hospitals, laboratories, diagnostic centres and wellness clinics) to upload sequencing data and automatically generate individualised microbiome reports.

Generation Two

Enbiosis SA — The Nutraceutical Formulation Engine

If Enbioma was the best personalised-nutrition platform in the world, Enbiosis SA is a different category altogether. It marks the transition from AI-generated diet recommendations to condition-specific microbiome formulations — ready-to-consume nutraceutical powders designed for a targeted clinical outcome.

Unlike traditional approaches that simply add beneficial microbes to the gut, Enbiosis SA instructs the existing microbiome to manufacture the molecules that the body needs. The gut becomes a programmable bioreactor, producing or suppressing specific metabolites precisely where they are needed.

The engine can now target more than 100 microbiome-related conditions — including diabetes, psoriasis, dry eye disease, inflammatory bowel disease and Alzheimer’s — and extends beyond condition management into enhancing energy, sleep quality, mood and cognitive performance.

Clinical Validation

The first results are already remarkable

The first Enbiosis SA clinical study, conducted in dry eye disease, delivered striking results: 100% of patients showed significant improvement, 62% achieved full recovery, and the Enbiosis SA formulation was 2× more effective than regulatory-approved drugs on the Schirmer test — the gold-standard clinical measure. Microbiome improvements remained sustained 16 weeks after the intervention ended.

60.7%

Improvement in tear production

+6mm

Schirmer test gain

62%

Full recovery rate

2×

More effective than approved drugs

Clinically validated · 8-week RCT & 8-week post-intervention · n=20. Pilot manuscript under journal review, publication expected in the first half of 2026.

Commercial Footprint

Deployed across four continents

Enbioma has been deployed by licensed partners internationally, with thousands of individual reports delivered to date.

Recognition & Achievements

Recognised by European deep tech and life sciences

UK Tech Rocketship Awards

Gold Medal · 2024
Awarded by the UK government (Department for Business and Trade) as one of the most promising technology companies from outside the UK — a flagship programme that effectively opened our UK market entry.

Sanofi

Country Winner · 2022

NutraIngredients Europe Awards

Finalist · 2023
The leading European award in the nutraceutical and functional-food industry.

UK Department for International Trade

Enbiosis SA was named one of the best technology companies across Europe (including Israel) at time of assessment.

Digestive Disease Week & IFM

Invited presentations of the multicentre IBS study, 2023.

Together, these milestones position Enbiosis SA not as a promising start-up, but as a mature, clinically-validated and globally recognised leader in AI-driven microbiome science.

Where we go from here

Food, engineered with the precision of software

Enbiosis SA was founded on a simple, ambitious thesis: that food, when engineered with the precision of software, can do the work of medicine. With Enbioma, we proved the thesis clinically. With Enbiosis SA, we turn it into a product category.

We are now partnering with health brands — in supplements, functional foods and beverages, and medical nutrition — to bring Enbiosis SA-designed formulations to consumers across South Africa and the wider region.

Upgrade Your Product Line with AI-Powered Blends

Partner with Enbiosis SA to access clinically-backed, ready-to-manufacture formulations tailored to your specific health categories.